BRPI0407658A - derivados de ácido aminofosfÈnico, seus sais e hidratos que atuam como moduladores de receptor de s1p e agente farmacêutico - Google Patents
derivados de ácido aminofosfÈnico, seus sais e hidratos que atuam como moduladores de receptor de s1p e agente farmacêuticoInfo
- Publication number
- BRPI0407658A BRPI0407658A BRPI0407658-3A BRPI0407658A BRPI0407658A BR PI0407658 A BRPI0407658 A BR PI0407658A BR PI0407658 A BRPI0407658 A BR PI0407658A BR PI0407658 A BRPI0407658 A BR PI0407658A
- Authority
- BR
- Brazil
- Prior art keywords
- act
- acid derivatives
- receptor modulators
- hydrates
- salts
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C47/00—Compounds having —CHO groups
- C07C47/52—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings
- C07C47/575—Compounds having —CHO groups bound to carbon atoms of six—membered aromatic rings containing ether groups, groups, groups, or groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
- C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
- C07C45/68—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
- C07C45/70—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction with functional groups containing oxygen only in singly bound form
- C07C45/71—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction with functional groups containing oxygen only in singly bound form being hydroxy groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic System
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids RP(=O)(OH)2; Thiophosphonic acids, i.e. RP(=X)(XH)2 (X = S, Se)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids RP(=O)(OH)2; Thiophosphonic acids, i.e. RP(=X)(XH)2 (X = S, Se)
- C07F9/3804—Phosphonic acids RP(=O)(OH)2; Thiophosphonic acids, i.e. RP(=X)(XH)2 (X = S, Se) not used, see subgroups
- C07F9/3826—Acyclic unsaturated acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids RP(=O)(OH)2; Thiophosphonic acids, i.e. RP(=X)(XH)2 (X = S, Se)
- C07F9/3804—Phosphonic acids RP(=O)(OH)2; Thiophosphonic acids, i.e. RP(=X)(XH)2 (X = S, Se) not used, see subgroups
- C07F9/3882—Arylalkanephosphonic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids RP(=O)(OH)2; Thiophosphonic acids, i.e. RP(=X)(XH)2 (X = S, Se)
- C07F9/40—Esters thereof
- C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
- C07F9/4015—Esters of acyclic unsaturated acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids RP(=O)(OH)2; Thiophosphonic acids, i.e. RP(=X)(XH)2 (X = S, Se)
- C07F9/40—Esters thereof
- C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
- C07F9/4056—Esters of arylalkanephosphonic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6527—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and oxygen atoms as the only ring hetero atoms
- C07F9/653—Five-membered rings
Abstract
"DERIVADOS DE áCIDO AMINOFOSFÈNICO, SEUS SAIS E HIDRATOS QUE ATUAM COMO MODULADORES DE RECEPTOR DE S1P E AGENTE FARMACêUTICO". Derivados de ácido aminofosfónico (como 2-amino-5-¢4-(3-benziloxifeniltio)-2-clorofenil!-2-metilpentilfosfonato monoéster) são representados pela seguinte fórmula geral (1): e que agem como eficazes moduladores de receptor de S1P ao mesmo tempo em que causam menos efeitos colaterais.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003039269 | 2003-02-18 | ||
PCT/JP2004/001783 WO2004074297A1 (ja) | 2003-02-18 | 2004-02-18 | アミノホスホン酸誘導体とその付加塩及びs1p受容体調節剤 |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0407658A true BRPI0407658A (pt) | 2006-02-21 |
Family
ID=32905163
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0407658-3A BRPI0407658A (pt) | 2003-02-18 | 2004-02-18 | derivados de ácido aminofosfÈnico, seus sais e hidratos que atuam como moduladores de receptor de s1p e agente farmacêutico |
Country Status (17)
Country | Link |
---|---|
US (2) | US7456157B2 (pt) |
EP (2) | EP2172472B1 (pt) |
JP (1) | JP4564918B2 (pt) |
KR (1) | KR101005171B1 (pt) |
CN (1) | CN100344638C (pt) |
AT (1) | ATE504590T1 (pt) |
AU (1) | AU2004213297B2 (pt) |
BR (1) | BRPI0407658A (pt) |
CA (1) | CA2515574C (pt) |
CY (1) | CY1111529T1 (pt) |
DE (1) | DE602004032118D1 (pt) |
DK (1) | DK1602660T3 (pt) |
ES (1) | ES2360394T3 (pt) |
MX (1) | MXPA05008760A (pt) |
PT (1) | PT1602660E (pt) |
SI (1) | SI1602660T1 (pt) |
WO (1) | WO2004074297A1 (pt) |
Families Citing this family (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101003877B1 (ko) * | 2002-09-19 | 2010-12-30 | 교린 세이야꾸 가부시키 가이샤 | 아미노알코올 유도체와 그 부가염 및 면역 억제제 |
CN100344638C (zh) * | 2003-02-18 | 2007-10-24 | 杏林制药株式会社 | 氨基膦酸衍生物、其加成盐以及s1p受体调节剂 |
US7638637B2 (en) | 2003-11-03 | 2009-12-29 | University Of Virginia Patent Foundation | Orally available sphingosine 1-phosphate receptor agonists and antagonists |
ATE502630T1 (de) * | 2004-07-16 | 2011-04-15 | Kyorin Seiyaku Kk | Verfahren zur effektiven anwendung eines medikaments und verfahren zur prävention von nebenwirkungen |
AU2005272619A1 (en) | 2004-08-13 | 2006-02-23 | Praecis Pharmaceuticals, Inc. | Methods and compositions for modulating sphingosine-1-phosphate (SIP) receptor activity |
US20060223866A1 (en) * | 2004-08-13 | 2006-10-05 | Praecis Pharmaceuticals, Inc. | Methods and compositions for modulating sphingosine-1-phosphate (S1P) receptor activity |
RU2376285C2 (ru) * | 2004-10-12 | 2009-12-20 | Киорин Фармасьютикал Ко., Лтд. | Процесс получения гидрохлорида 2-амино-2-[2-[4-(3-бензилоксифенилтио)-2-хлорфенилэтил]-1,3-пропандиола] и его гидратов, а также промежуточные продукты их получения |
MX2007006706A (es) | 2004-12-06 | 2007-10-18 | Univ Virginia | Analogos de esfingosina 1-fosfato amida de arilo. |
SI2295049T1 (sl) * | 2005-09-09 | 2015-03-31 | Novartis Ag | Zdravljenje avtoimunskih bolezni |
RU2421214C2 (ru) * | 2005-10-07 | 2011-06-20 | Киорин Фармасьютикал Ко., Лтд. | Терапевтическое средство для лечения гепатита и способ лечения гепатита |
BRPI0707281A2 (pt) | 2006-01-27 | 2011-04-26 | Univ Virginia | método para prevenção ou tratamento de dor neuropática em um mamìfero |
TWI389683B (zh) * | 2006-02-06 | 2013-03-21 | Kyorin Seiyaku Kk | A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient |
WO2007092638A1 (en) | 2006-02-09 | 2007-08-16 | University Of Virginia Patent Foundation | Bicyclic sphingosine 1-phosphate analogs |
WO2008019090A2 (en) * | 2006-08-04 | 2008-02-14 | Praecis Pharmaceuticals Incorporated | Agonists of the sphingosine-1-phosphate receptor |
MY152176A (en) | 2006-08-08 | 2014-08-15 | Kyorin Seiyaku Kk | Amino phosphate derivative and s1p receptor modulator having same as an active ingredient |
SG174029A1 (en) * | 2006-08-08 | 2011-09-29 | Kyorin Seiyaku Kk | Aminoalcohol derivative and immunosuppressant containing the same as active ingredient |
AU2007323618A1 (en) | 2006-11-21 | 2008-05-29 | University Of Virginia Patent Foundation | Tetralin analogs having sphingosine 1-phosphate agonist activity |
WO2008064320A2 (en) | 2006-11-21 | 2008-05-29 | University Of Virginia Patent Foundation | Hydrindane analogs having sphingosine 1-phosphate receptor agonist activity |
EP2097371A2 (en) * | 2006-11-21 | 2009-09-09 | University Of Virginia Patent Foundation | Benzocycloheptyl analogs having sphingosine 1-phosphate receptor activity |
PL2952177T3 (pl) | 2007-10-12 | 2021-07-19 | Novartis Ag | Kompozycje zawierające modulatory receptora fosforanu sfingozyny 1 (s1p) |
JP5452237B2 (ja) | 2008-02-07 | 2014-03-26 | 杏林製薬株式会社 | アミノアルコール誘導体を有効成分とする炎症性腸疾患の治療剤又は予防剤 |
US9493410B2 (en) * | 2008-03-24 | 2016-11-15 | Kyorin Pharmaceutical Co., Ltd. | Method for crystallization of 2-amino-2-[2-[4-(3-benzyloxyphenylthio)-2-chlorophenyl]-ethyl]-1,3-propanediol hydrochloride |
US20110077427A1 (en) * | 2008-05-19 | 2011-03-31 | Kyorin Pharmaceutical Co., Ltd. | Method for producing optically active aminoalcohol derivative |
SG191598A1 (en) * | 2008-05-20 | 2013-07-31 | Kyorin Seiyaku Kk | Agent for induction/maintenance of remission |
KR20190004843A (ko) | 2008-07-23 | 2019-01-14 | 아레나 파마슈티칼스, 인크. | 자가면역성 및 염증성의 장애의 치료에 유용한 치환된 1,2,3,4-테트라히드로시클로펜타[b]인돌-3-일)아세트산 유도체 |
CA2733390A1 (en) | 2008-08-01 | 2010-02-04 | Bioxiness Pharmaceuticals, Inc. | Methionine analogs and methods of using same |
US8415484B2 (en) | 2008-08-27 | 2013-04-09 | Arena Pharmaceuticals, Inc. | Substituted tricyclic acid derivatives as S1P1 receptor agonists useful in the treatment of autoimmune and inflammatory disorders |
CA2740484C (en) * | 2008-10-17 | 2021-09-21 | Akaal Pharma Pty Ltd | S1p receptors modulators and their use thereof |
JP5616342B2 (ja) * | 2009-07-09 | 2014-10-29 | 杏林製薬株式会社 | ジフェニルスルフィド誘導体及びそれらを有効成分とする医薬 |
EP4148045A1 (en) | 2010-01-27 | 2023-03-15 | Arena Pharmaceuticals, Inc. | Intermediate compounds for the preparation of (r)-2-(7-(4-cyclopentyl-3- (trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b] indol-3-yl)acetic acid and salts thereof |
CA2789480A1 (en) | 2010-03-03 | 2011-09-09 | Arena Pharmaceuticals, Inc. | Processes for the preparation of s1p1 receptor modulators and crystalline forms thereof |
SG185746A1 (en) | 2010-05-06 | 2013-01-30 | Novartis Ag | Treatment of autoimmune diseases |
JP2013525469A (ja) | 2010-05-06 | 2013-06-20 | ノバルティス アーゲー | ジアリールスルフィド誘導体の投与レジメン |
KR20130143091A (ko) * | 2010-11-22 | 2013-12-30 | 알러간, 인코포레이티드 | 치료적 유용성을 가지는 수용체 조절제로서의 신규한 화합물 |
TWI519539B (zh) * | 2010-12-21 | 2016-02-01 | Kyorin Seiyaku Kk | Diphenyl sulfide derivatives and pharmaceuticals as an active ingredient thereof |
US8673308B2 (en) | 2011-02-23 | 2014-03-18 | Als Therapy Development Institute | Targeting of CD8+ T-lymphocytes to treat neurodegenerative diseases |
WO2012136121A1 (zh) * | 2011-04-02 | 2012-10-11 | 中国人民解放军军事医学科学院毒物药物研究所 | 氨基苯丙醇类化合物及其用于制备免疫抑制剂的用途 |
US8946301B2 (en) | 2011-11-29 | 2015-02-03 | Als Therapy Development Institute | Targeting of T-lymphocytes to treat amyotrophic lateral sclerosis |
EP2842937B1 (en) | 2012-04-23 | 2018-01-17 | Mitsubishi Tanabe Pharma Corporation | Amine compound and use thereof for medical purposes |
MX2021011472A (es) | 2015-01-06 | 2022-08-17 | Arena Pharm Inc | Metodos de condiciones de tratamiento relacionadas con el receptor s1p1. |
PL3310760T3 (pl) | 2015-06-22 | 2023-03-06 | Arena Pharmaceuticals, Inc. | Krystaliczna sól L-argininy kwasu (R)-2-(7-(4-cyklopentylo-3-(trifluorometylo)benzyloksy)- 1,2,3,4-tetrahydrocyklo-penta[b]indol-3-ilo)octowego do zastosowania w zaburzeniach związanych z receptorem S1P1 |
CN110545848A (zh) | 2017-02-16 | 2019-12-06 | 艾尼纳制药公司 | 用于治疗具有肠外表现的炎症性肠病的化合物和方法 |
CN110520124A (zh) | 2017-02-16 | 2019-11-29 | 艾尼纳制药公司 | 用于治疗原发性胆汁性胆管炎的化合物和方法 |
WO2020051378A1 (en) | 2018-09-06 | 2020-03-12 | Arena Pharmaceuticals, Inc. | Compounds useful in the treatment of autoimmune and inflammatory disorders |
AU2021424131A1 (en) | 2021-01-28 | 2023-07-27 | Priothera Limited | Methods of treatment with s1p receptor modulators |
WO2022162088A2 (en) | 2021-01-28 | 2022-08-04 | Priothera Sas | Methods of treatment with s1p receptor modulators |
TW202341971A (zh) | 2022-02-16 | 2023-11-01 | 法商普萊歐塞拉公司 | 使用car細胞及s1p受體調節劑之治療方法 |
EP4282407A1 (en) | 2022-05-27 | 2023-11-29 | Priothera SAS | Treatment of cancer with s1p receptor agonists |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5447922A (en) * | 1994-08-24 | 1995-09-05 | Bristol-Myers Squibb Company | α-phosphonosulfinic squalene synthetase inhibitors |
AU2001264313A1 (en) | 2000-06-20 | 2002-01-02 | Japan Tobacco Inc. | Pyrazolopyridine compounds and use thereof as drugs |
AU2001285331B2 (en) | 2000-08-31 | 2006-04-06 | Merck & Co., Inc. | Phosphate derivatives as immunoregulatory agents |
US7064217B2 (en) * | 2001-01-30 | 2006-06-20 | University Of Virginia Patent Foundation | Agonists and antagonists of sphingosine-1-phosphate receptors |
DE60234318D1 (de) | 2001-02-08 | 2009-12-24 | Ono Pharmaceutical Co | Mittel zur behandlung von harnwegserkrankungen, umfassend mittel zur kontrolle des lpa-rezeptors |
CZ20032560A3 (cs) | 2001-03-26 | 2003-12-17 | Novartis Ag | Deriváty 2-aminopropanolu, způsob jejich přípravy a farmaceutický prostředek, který je obsahuje |
ATE416762T1 (de) * | 2001-05-10 | 2008-12-15 | Ono Pharmaceutical Co | Carbonsäurederivate und diese als wirkstoff enthaltende arzneimittel |
EP1424078A4 (en) * | 2001-09-04 | 2009-03-25 | Ono Pharmaceutical Co | RESPIRATORY DISEASE MEDICINES COMPRISING A SPHINGOSINE-1-PHOSPHATE RECEPTOR REGULATING AGENT |
JP2005112721A (ja) | 2001-11-06 | 2005-04-28 | Maruha Corp | 含窒素化合物、製造法、及びその利用方法 |
JP4035759B2 (ja) | 2001-11-06 | 2008-01-23 | 独立行政法人産業技術総合研究所 | アミノアルコールリン酸化合物、製造方法、及びその利用方法 |
AU2002354476A1 (en) | 2001-12-14 | 2003-06-30 | Japan Tobacco Inc. | Pyrazolopyridine derivatives and medicinal use thereof |
EP1470137B1 (en) | 2002-01-18 | 2009-09-02 | Merck & Co., Inc. | Edg receptor agonists |
WO2003062248A2 (en) | 2002-01-18 | 2003-07-31 | Merck & Co., Inc. | N-(benzyl)aminoalkylcarboxylates, phosphinates, phosphonates and tetrazoles as edg receptor agonists |
WO2003061567A2 (en) * | 2002-01-18 | 2003-07-31 | Merck & Co., Inc. | Selective s1p1/edg1 receptor agonists |
US7309721B2 (en) | 2002-03-01 | 2007-12-18 | Merck + Co., Inc. | Aminoalkylphosphonates and related compounds as Edg receptor agonists |
EP1944026B1 (en) * | 2002-05-16 | 2013-06-26 | Novartis AG | Use of EDG receptor binding agents in cancer |
CA2497067A1 (en) * | 2002-09-13 | 2004-03-25 | Novartis Ag | Amino-propanol derivatives |
ES2393551T3 (es) * | 2003-02-11 | 2012-12-26 | Irm Llc | Compuestos bicíclicos novedosos y composiciones |
CN100344638C (zh) * | 2003-02-18 | 2007-10-24 | 杏林制药株式会社 | 氨基膦酸衍生物、其加成盐以及s1p受体调节剂 |
-
2004
- 2004-02-18 CN CNB200480004551XA patent/CN100344638C/zh not_active Expired - Fee Related
- 2004-02-18 PT PT04712184T patent/PT1602660E/pt unknown
- 2004-02-18 US US10/545,790 patent/US7456157B2/en active Active
- 2004-02-18 KR KR1020057015237A patent/KR101005171B1/ko not_active IP Right Cessation
- 2004-02-18 EP EP09178067A patent/EP2172472B1/en not_active Expired - Lifetime
- 2004-02-18 SI SI200431656T patent/SI1602660T1/sl unknown
- 2004-02-18 ES ES04712184T patent/ES2360394T3/es not_active Expired - Lifetime
- 2004-02-18 JP JP2005502730A patent/JP4564918B2/ja not_active Expired - Fee Related
- 2004-02-18 WO PCT/JP2004/001783 patent/WO2004074297A1/ja active Application Filing
- 2004-02-18 DK DK04712184.3T patent/DK1602660T3/da active
- 2004-02-18 MX MXPA05008760A patent/MXPA05008760A/es active IP Right Grant
- 2004-02-18 DE DE602004032118T patent/DE602004032118D1/de not_active Expired - Lifetime
- 2004-02-18 BR BRPI0407658-3A patent/BRPI0407658A/pt not_active Application Discontinuation
- 2004-02-18 AU AU2004213297A patent/AU2004213297B2/en not_active Ceased
- 2004-02-18 CA CA2515574A patent/CA2515574C/en not_active Expired - Fee Related
- 2004-02-18 EP EP04712184A patent/EP1602660B1/en not_active Expired - Lifetime
- 2004-02-18 AT AT04712184T patent/ATE504590T1/de active
-
2008
- 2008-06-16 US US12/213,187 patent/US7759326B2/en not_active Expired - Fee Related
-
2011
- 2011-06-06 CY CY20111100542T patent/CY1111529T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
JPWO2004074297A1 (ja) | 2006-06-01 |
JP4564918B2 (ja) | 2010-10-20 |
EP1602660B1 (en) | 2011-04-06 |
SI1602660T1 (sl) | 2011-06-30 |
WO2004074297A1 (ja) | 2004-09-02 |
ATE504590T1 (de) | 2011-04-15 |
MXPA05008760A (es) | 2006-03-21 |
ES2360394T3 (es) | 2011-06-03 |
CY1111529T1 (el) | 2015-08-05 |
AU2004213297B2 (en) | 2009-03-19 |
CN1751054A (zh) | 2006-03-22 |
EP2172472B1 (en) | 2012-12-26 |
DK1602660T3 (da) | 2011-05-23 |
DE602004032118D1 (de) | 2011-05-19 |
CA2515574A1 (en) | 2004-09-02 |
US7456157B2 (en) | 2008-11-25 |
EP2172472A2 (en) | 2010-04-07 |
KR101005171B1 (ko) | 2011-01-04 |
US20060160771A1 (en) | 2006-07-20 |
EP1602660A4 (en) | 2008-03-19 |
EP2172472A3 (en) | 2010-06-30 |
CN100344638C (zh) | 2007-10-24 |
CA2515574C (en) | 2012-03-13 |
PT1602660E (pt) | 2011-06-15 |
AU2004213297A1 (en) | 2004-09-02 |
EP1602660A1 (en) | 2005-12-07 |
US7759326B2 (en) | 2010-07-20 |
US20080275008A1 (en) | 2008-11-06 |
KR20050109069A (ko) | 2005-11-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0407658A (pt) | derivados de ácido aminofosfÈnico, seus sais e hidratos que atuam como moduladores de receptor de s1p e agente farmacêutico | |
CO7101251A2 (es) | Derivado de sulfuro de alquil fenilo y agente de control de plagas | |
GT200600496A (es) | Sales, profarmacos y formulaciones de 1-[5-(4-amino-7-isopropil-7h-pirrolo[2,3-d]piirimidin-5-carbonil)-2-metoxi-feil]-3-(2,4-dicloro-fenil)-urea. | |
NO20006251L (no) | Benzotiepin-1,1-dioksidderivater, fremgangsmåte for deres fremstilling, legemidler som inneholder disse forbindelsene og deres anvendelse | |
TW200734314A (en) | Piperazine compounds having herbicidal action | |
NO20062689L (no) | Azabisykliske heterosykler som modulatorer for kannabinoidreseptorer | |
HK1138735A1 (en) | Disinfectant | |
CY1112429T1 (el) | Υποκατεστημενα παραγωγα σουλφοναμιδιου | |
AR067309A1 (es) | Formulaciones farmaceuticas que contienen derivados de acido lipoico | |
HRP20120323T1 (en) | Diarylhydantoin compounds | |
BRPI0713378A8 (pt) | composto, pró-droga, modulador da função do receptor gpr40, agente farmacêutico uso do composto, e, método de produção de uma forma opticamente ativa de um composto | |
BR0109703A (pt) | Derivados de piperazina | |
BRPI0621446B8 (pt) | composição farmacêutica para uso externo | |
RS52780B (en) | MEANS OF PREVENTION AND TREATMENT OF DISORDERS CONCERNING MODULATION OF RYR RECEPTORS | |
ECSP055582A (es) | Derivados de benzotiazol que tienen actividad agonista de beta-2-adrenorreceptor | |
DK2368887T3 (da) | 1, 2, 3-triazolderivater til anvendelse som stearoyl-coa desaturase-inhibitorer | |
DK1694318T3 (da) | (S)-2-N-propylamino-5-hydroxytetralin som D3-agonistisk terapeutikum | |
NO20076357L (no) | Azabicykliske heterocykler som cannabinoid reseptor modulatorer | |
ES2421948T3 (es) | Compuestos y composiciones para suministrar agentes activos | |
RS52108B (en) | 3-SUBSTITUTED [1,2,3] -BENZOTRIAZINONE UNIT TO INCREASE GLUTAMATERGIC SYNAPTIC ANSWERS | |
BRPI0317188A2 (pt) | Novo derivado de 2,4-diamino-1,3,5-triazina | |
UY27910A1 (es) | Uso de un derivado de amina cíclica específico o de sus sales farmacéuticamente aceptables para tratar o prevenir la insuficiencia cardiaca | |
CL2008001912A1 (es) | Procedimiento de preparacion de compuestos derivados de bencimidazol tienilamina, utiles como agentes inhibidores del agente de intercambio sodio/proton del tipo 3; compuestos intermediarios. | |
NO20063617L (no) | Diarylmetylidenpiperidinderivater, fremstilling og anvendelse derav | |
AR117988A1 (es) | Medicamento para profilaxis o tratamiento para la fibrosis pulmonar |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A ANUIDADE. PAGAR RESTAURACAO. |
|
B08H | Application fees: decision cancelled [chapter 8.8 patent gazette] |
Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 2259 DE 22/04/2014 |
|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL |